Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: zinc finger DNA-binding protein nucleases - Sangamo Therapeutics

Drug Profile

Research programme: zinc finger DNA-binding protein nucleases - Sangamo Therapeutics

Alternative Names: SB-LSD3; SB-LSD4; ZFN Bcl11a; ZFN therapeutics - Sangamo; ZFP nucleases - Sangamo

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sangamo BioSciences
  • Developer Sangamo Therapeutics; University of Massachusetts Medical School
  • Class Antineoplastics; Cell therapies; Gene therapies; Stem cell therapies; Zinc finger DNA binding proteins
  • Mechanism of Action Alpha 1 antitrypsin modulators; CCR5 receptor modulators; Cell replacements; Gene modulators; Gene silencing; Genetic transcription inhibitors; Interleukin 2 receptor modulators; T-cell receptor gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • New Molecular Entity No

Highest Development Phases

  • No development reported Alpha 1-antitrypsin deficiency; Cancer; Down syndrome; HIV infections; Immunodeficiency disorders; Mucopolysaccharidosis I; Mucopolysaccharidosis II

Most Recent Events

  • 07 Feb 2018 Case Western Reserve University and Sangamo Therapeutics plans a phase I trial for HIV infections in USA in 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top